Medpace Holdings Inc vs SentinelOne Inc. Class A Common Stock — how do they compare? Medpace Holdings Inc trades at $614.63 (market cap $16.82B), while SentinelOne Inc. Class A Common Stock trades at $26.47 (market cap $8.84B). The key difference: Medpace Holdings Inc is the larger of the two by market cap, and SentinelOne Inc. Class A Common Stock is trading nearer its 52-week high, Medpace Holdings Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and SentinelOne Inc. Class A Common Stock for 0 Days on average.
| MEDP | S | |
|---|---|---|
Market Cap | $16.82B | $8.84B |
Volume | 223,093 | 7,515,091 |
Sector | Health | Technology |
52-Week High | $630.19 | $25.80 |
52-Week Low | $393.42 | $11.94 |
Typical Hold Time | 14 Days | 0 Days |
Enterprise Value | $16.44B | $8.23B |
Signals from Pluang's Aura AI — not financial advice
MEDP trades at $604.25, up 0.22% today, with a neutral technical signal and strong fundamental performance. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected on October 21, 2026. Revenue grew to $2.53 billion in 2025, with a net income margin of 17.67% and robust ROE of 162.15%. Analyst consensus is a $620.44 price target, though institutional sentiment is mixed with recent CEO share sales.
Outlook remains positive given earnings momentum and projected 2026 revenue growth to $2.8 billion. Key risks include high valuation multiples and insider selling. The stock offers upside to consensus target but requires monitoring of Q3 earnings and competitive pressures in medical services.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →SentinelOne provides an AI-powered cybersecurity platform for organizations. Its Singularity platform helps detect, prevent, and respond to threats across endpoints, cloud workloads, identities, and connected devices.
Read more on S →